Helix Biopharma Corp. Appoints Dr. Frank Gary Renshaw as Chief Medical Officer

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce the appointment of Dr. Frank Gary Renshaw, as the Chief Medical Officer.


Helix – Gary CMO – Oct 3, 2022